<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01347671</url>
  </required_header>
  <id_info>
    <org_study_id>430409</org_study_id>
    <secondary_id>2010-022557-42</secondary_id>
    <nct_id>NCT01347671</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of GRT6005 in Pain Due to Diabetic Polyneuropathy</brief_title>
  <official_title>A Randomized 4-week Phase IIa Trial Evaluating the Efficacy, Safety, and Tolerability of GRT6005, a New Centrally Acting Analgesic, in Subjects With Pain Due to Diabetic Polyneuropathy.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Grünenthal GmbH</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Forest Laboratories</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Grünenthal GmbH</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this trial is to investigate the efficacy and safety of GRT6005 in patients
      with painful diabetic neuropathy.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2011</start_date>
  <completion_date type="Actual">January 2012</completion_date>
  <primary_completion_date type="Actual">January 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in mean daily pain intensity score</measure>
    <time_frame>Baseline to Week 4</time_frame>
    <description>Participants will be selected based on their medical history and clinical examination.
Efficacy of the treatment (i.e., reduction of pain) will be evaluated with the 11-point numeric rating scale (NRS), where 0 represents no pain and 10 represents &quot;pain as bad as you can imagine&quot;.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Response measured in percentage change of pain intensity from baseline</measure>
    <time_frame>End of 4 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Quantitative Sensory Testing from baseline</measure>
    <time_frame>Baseline, week 1 and week 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neuropathic Pain Scale, changes from baseline</measure>
    <time_frame>End of 4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Short Form of the Brief Pain Inventory, changes from baseline</measure>
    <time_frame>End of 4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Leeds Sleep Evaluation Questionnaire</measure>
    <time_frame>End of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life Index -Short-Form-12®, from baseline</measure>
    <time_frame>End of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient's Global Impression of Change</measure>
    <time_frame>End of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life EuroQoL-5 Dimension score, change from baseline</measure>
    <time_frame>End of 4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rescue medication use</measure>
    <time_frame>End of 4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Opioid Withdrawal Scale</measure>
    <time_frame>End of 4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma concentration</measure>
    <time_frame>End of 4 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">189</enrollment>
  <condition>Pain</condition>
  <condition>Diabetic Neuropathies</condition>
  <arm_group>
    <arm_group_label>25 µg GRT6005</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants allocated to this treatment arm will receive a daily dose of 25 µg GRT6005 per day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>75 µg GRT6005</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants allocated to this treatment arm will receive a daily dose of 75 µg GRT6005 per day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>200 µg GRT6005</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants allocated to this treatment arm will receive a daily dose of 200 µg GRT6005 per day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Matching Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants allocated to this treatment arm will receive a dose of matched placebo once a day.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GRT6005</intervention_name>
    <description>25µg/day once daily</description>
    <arm_group_label>25 µg GRT6005</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GRT6005</intervention_name>
    <description>75 µg/day once daily</description>
    <arm_group_label>75 µg GRT6005</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GRT6005</intervention_name>
    <description>200 µg/day once daily</description>
    <arm_group_label>200 µg GRT6005</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Matching Placebo</intervention_name>
    <description>Once daily</description>
    <arm_group_label>Matching Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Men and women, 18 to 75 years old.

          -  Type 1 or type 2 diabetes.

          -  Painful DPN symptoms and signs for at least 3 months.

          -  Blood glucose controlled with medication.

          -  Glycosylated hemoglobin not greater than 9.5 or 11%, country dependent.

          -  Prior analgesic medication.

          -  Average score of 4 or greater on the 11 point NRS during the last 3 days prior to
             randomization.

        Exclusion Criteria:

          -  Impaired liver, cardiac or renal function.

          -  Breastfeeding and pregnancy.

          -  History of substance abuse, alcohol or medication.

          -  Chronic gastrointestinal disease.

          -  History of seizures and or epilepsy.

          -  History or presence of malignancy.

          -  Presence of painful medical conditions that are not due to diabetic neuropathy, e.g.
             rheumatoid arthritis.

          -  Allergies to opioids, acetaminophen or excipients of the medications.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thomas Forst, Prof. Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>ikfe GmbH, Institut for Klinische Forschung und Entwicklung, Parcusstr. 8, 55116 Mainz, Germany</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Site 4502</name>
      <address>
        <city>Sofia</city>
        <zip>1431</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 4112</name>
      <address>
        <city>Aschaffenburg</city>
        <zip>63739</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 4109</name>
      <address>
        <city>Bad Oeynhausen</city>
        <zip>32545</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 4101</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 4110</name>
      <address>
        <city>Berlin</city>
        <zip>13125</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 4111</name>
      <address>
        <city>Dresden</city>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 4107</name>
      <address>
        <city>Hamburg</city>
        <zip>20253</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 4117</name>
      <address>
        <city>Hamburg</city>
        <zip>22587</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 4108</name>
      <address>
        <city>Hannover</city>
        <zip>30159</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 4104</name>
      <address>
        <city>Hannover</city>
        <zip>30167</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 4115</name>
      <address>
        <city>Heidelberg</city>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 4106</name>
      <address>
        <city>Kiel</city>
        <zip>24119</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 4102</name>
      <address>
        <city>Lübeck</city>
        <zip>23562</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>4103</name>
      <address>
        <city>Mainz</city>
        <zip>55116</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 4105</name>
      <address>
        <city>Münster</city>
        <zip>48145</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 4113</name>
      <address>
        <city>Schwerin</city>
        <zip>19055</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 4116</name>
      <address>
        <city>Wangen</city>
        <zip>88239</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 4405</name>
      <address>
        <city>Bucuresti</city>
        <zip>010496</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 4402</name>
      <address>
        <city>Bucuresti</city>
        <zip>011025</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 4407</name>
      <address>
        <city>Sibiu</city>
        <zip>550166</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 4401</name>
      <address>
        <city>Tg. Mures</city>
        <zip>540139</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 4406</name>
      <address>
        <city>Timisoara</city>
        <zip>300594</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Bulgaria</country>
    <country>Germany</country>
    <country>Romania</country>
  </location_countries>
  <verification_date>June 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 2, 2011</study_first_submitted>
  <study_first_submitted_qc>May 3, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 4, 2011</study_first_posted>
  <last_update_submitted>June 5, 2012</last_update_submitted>
  <last_update_submitted_qc>June 5, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 6, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>analgesia</keyword>
  <keyword>analgesics</keyword>
  <keyword>pain</keyword>
  <keyword>chronic pain</keyword>
  <keyword>neuropathic pain</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetic Neuropathies</mesh_term>
    <mesh_term>Polyneuropathies</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Analgesics</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

